Moreover, as it is reported that dual inhibition of JAK2 and Stat5 enhances killing of myeloproliferative neoplasia cells [45], JAK2 inhibitors are likely to produce more benefit when combined with Stat5 inhibitors in the treatment of F/P(+) CEL. The gene discussed is JAK2; the disease is Chronic Eosinophilic Leukemia, Not Otherwise Specified.